Skip to main content
SpringerLink
Log in

Recent R&D Highlights

  • News & Views
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table 1

Notes

  1. Colorectal Oral Novel Therapy for the Inhibition of Angiogenesis and Retarding of Metastases in First-line.

  2. Colorectal Oral Novel Therapy for the Inhibition of Angiogenesis and Retarding of Metastases in Second-lioe.

  3. Growth Arrest with Oral Anti-Angiogenesis in Lung Cancer.

  4. The studies were funded by the US National Cancer Instirute.

References

  1. Schering AG. PTK/ZK CONFIRM 1 phase in study shows positive drug effects in metastatic colorectal cancer-filing now anticipated for early 2007. Media release: 21 Mar 2005

  2. European Pharmaceuticals. Schering AG -PTK data disappointing but −14% reaction overdone. Lehman Brothers Equity Research (2005)

  3. Georgia Institute of Technology. Cancer-fighting power promising for synthetic cell-signaling molecule. Media release: 19 Apr 2005

  4. University of Michigan Health System. Compound from Chinese medicine shows promise in head and neck cancer. Media release: 15 Apr 2005

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 3, 11–13 (2005). https://doi.org/10.1007/BF03262546

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262546

Search

Navigation